Study Stopped
Impact of COVID-19 on Recruitment
A Full-Arch Implant- Supported Prosthesis in the Upper and/or Lower Jaw-USA
A Prospective, Single-Centre, Post-Market Study to Evaluate the Use of Polyetheretherketone (PEEK) Full-Arch Implant-Supported Prostheses in the Edentulous Jaw
1 other identifier
observational
10
1 country
1
Brief Summary
This study follows subjects who have agreed with their dentist that their failing teeth or missing teeth all need replacing. This study follows their standard routine care with some additional assessments. The dental treatment option that replaces a whole arch or both arches (upper and lower jaws) of the mouth is call "Teeth in a Day" and information on the use of the JUVORA™ Dental Disc during this treatment is what is being collected as part of this study along with subjects follow-up care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Aug 2018
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 7, 2018
CompletedFirst Submitted
Initial submission to the registry
August 8, 2018
CompletedFirst Posted
Study publicly available on registry
September 4, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 3, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
May 3, 2022
CompletedMay 11, 2022
March 1, 2022
3.7 years
August 8, 2018
May 5, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Survival of the Prosthetic
Survival will be evaluated using the ITI Treatment Guide Volume 8 - Survival is defined as "is the prosthesis present in the mouth at the time of assessment ("presence or absence")
12 months
Secondary Outcomes (16)
Patient quality of life assessment using a patient questionnaire.
6 weeks 6 & 12 months
Oral and dental:Patients will be assessed for a history of Bruxism (grinding of the teeth).
6 weeks 6 &12 months
Oral and dental: Patients will be checked for occlusion.
6 weeks &12 months
Survival of the implant in the patients mouth.
12 months
Success of the implant in the patients mouth.
12 months
- +11 more secondary outcomes
Other Outcomes (1)
Technical Satisfaction not related to the patient
between 4 - 6 months prior to fixture in the patients mouth.
Study Arms (1)
Treatment with the JUVORA™ Dental Disc
Subjects receive the device as per normal standard practice, there are no other treatment arms for this prospective study.
Interventions
treatment with the JUVORA™ Dental Disc
Eligibility Criteria
Patients indicated to receive a full-arch implant-supported prosthesis in a single jaw (mandibular or maxillary) or full-arch implant-supported prosthesis in both jaws (mandibular and maxillary).
You may qualify if:
- Subjects aged 18 years or older in need of a full-arch implant supported rehabilitation in a single jaw (mandibular or maxillary) or both edentulous jaws (mandibular and maxillary).
- Subjects with adequate bone quality and quantity to allow the placement of a minimum of four Neodent implants into the arch area.
- Subjects who, in the opinion of the Investigator, are able to understand this clinical study, co-operate with the procedures and are willing to return to the clinic for all the required post-operative follow-ups.
- Subjects who are able to give voluntary, written informed consent to participate in this clinical study and from whom consent has been obtained.
You may not qualify if:
- Female subjects who are pregnant or lactating.
- Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.
- Subjects with any condition that would compromise their participation and follow-up in this clinical study.
- Subjects with insufficient bone volume or quality in the edentulous jaw.
- Subjects on any chemotherapeutic or bisphosphonate medications.
- Subjects with evidence of tumour and/or malignant disease with resultant life expectancy of less than 2 years.
- Subjects who smoke more than 10 cigarettes per day.
- Subjects who are currently enrolled in another clinical study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Juvora Ltd.lead
- PCG Clinical Servicescollaborator
Study Sites (1)
Dr Robert Lemke
San Antonio, Texas, 78216, United States
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Juvora
Juvora Ltd.
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 8, 2018
First Posted
September 4, 2018
Study Start
August 7, 2018
Primary Completion
May 3, 2022
Study Completion
May 3, 2022
Last Updated
May 11, 2022
Record last verified: 2022-03
Data Sharing
- IPD Sharing
- Will not share